媒体点赞机构买入，“走红”抗癌药来自“广州制造”

广州日报2025-03-07

近期一款“名不见经传”的抗癌药走红。广州日报新花城记者采访获悉：这款药物来自“广州制造”——广州康方药业生产的依沃西是全球首创双特异性抗体新药（商品名“依达方® ”），不但可以消灭肿瘤，还能抑制肿瘤血管生长，抑制肿瘤扩散。　　3月7日，康方生物方面回复广州日报新花城记者称：康方生物依沃西是备受关注的全球抗肿瘤“明星药”，2022年，康方生物将依沃西的部分海外权益，以高达50亿美元的总交易额，外加2...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517809494?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-07 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517809494","market":"us","top_or_hot":-1,"title":"媒体点赞机构买入，“走红”抗癌药来自“广州制造”","media":"广州日报","content":"<div>\n<p>近期一款“名不见经传”的抗癌药走红。广州日报新花城记者采访获悉：这款药物来自“广州制造”——广州康方药业生产的依沃西是全球首创双特异性抗体新药（商品名“依达方® ”），不但可以消灭肿瘤，还能抑制肿瘤血管生长，抑制肿瘤扩散。　　3月7日，康方生物方面回复广州日报新花城记者称：康方生物依沃西是备受关注的全球抗肿瘤“明星药”，2022年，康方生物将依沃西的部分海外权益，以高达50亿美元的总交易额，外加2...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202503073339990630.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>媒体点赞机构买入，“走红”抗癌药来自“广州制造”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n媒体点赞机构买入，“走红”抗癌药来自“广州制造”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-07 20:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202503073339990630.html><strong>广州日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近期一款“名不见经传”的抗癌药走红。广州日报新花城记者采访获悉：这款药物来自“广州制造”——广州康方药业生产的依沃西是全球首创双特异性抗体新药（商品名“依达方® ”），不但可以消灭肿瘤，还能抑制肿瘤血管生长，抑制肿瘤扩散。　　3月7日，康方生物方面回复广州日报新花城记者称：康方生物依沃西是备受关注的全球抗肿瘤“明星药”，2022年，康方生物将依沃西的部分海外权益，以高达50亿美元的总交易额，外加2...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202503073339990630.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989772923.USD","symbol_name":"CPR Invest - Climate Action A2 Acc USD-H","start_time":0,"source_url":"http://finance.eastmoney.com/a/202503073339990630.html","article_id":"2517809494","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517809494","pubTimestamp":1741352152,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"近期一款“名不见经传”的抗癌药走红。广州日报新花城记者采访获悉：这款药物来自“广州制造”——广州康方药业生产的依沃西是全球首创双特异性抗体新药（商品名“依达方?”），不但可以消灭肿瘤，还能抑制肿瘤血管生长，抑制肿瘤扩散。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","09926":"康方生物","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0861579265.USD":"联博低波幅策略股票基金A","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","MRK":"默沙东"},"translate_title":"Media praises institutions to buy, \"popular\" anticancer drugs come from \"Made in Guangzhou\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.6,"MRK":0.6},"content_text":"近期一款“名不见经传”的抗癌药走红。广州日报新花城记者采访获悉：这款药物来自“广州制造”——广州康方药业生产的依沃西是全球首创双特异性抗体新药（商品名“依达方® ”），不但可以消灭肿瘤，还能抑制肿瘤血管生长，抑制肿瘤扩散。　　3月7日，康方生物方面回复广州日报新花城记者称：康方生物依沃西是备受关注的全球抗肿瘤“明星药”，2022年，康方生物将依沃西的部分海外权益，以高达50亿美元的总交易额，外加2位数销售提成的方案，许可给美国Summit公司，刷新了中国单药海外授权的历史纪录。　　据悉，依沃西已经获批上市用于治疗非小细胞肺癌。2024年12月，依达方®通过国家医保谈判进入国家医保目录，相关患者疾病负担明显下降。　　据了解，在美国举办的世界肺癌大会上，康方生物的全球首创双特异性抗体新药依沃西对比帕博利珠单抗（K药）一线治疗PD-L1表达阳性的非小细胞肺癌的Ⅲ期临床研究（HARMONi-2）数据正式发布。研究结果显示，依沃西取得了11.14个月的中位无进展生存期，K药取得了5.82个月的中位无进展生存期。对比K药，依沃西能延长患者无进展生存期达5.32个月，疾病进展/死亡风险降低49%，研究无进展生存期的风险比达到0.51。据悉，这创造了全球非小细胞肺癌治疗最长无进展生存期。　　近日，康方生物自主研发的全球首创双抗新药依沃西HARMONi-2的研究数据荣登国际顶级医学期刊《柳叶刀》（The Lancet）。HARMONi-2是一项依沃西对比全球销售“药王”帕博利珠单抗一线治疗PD-L1表达阳性的非小细胞肺癌的随机、双盲、对照研究。有媒体称：这是“抗癌药的”中国时刻。　　国内有业界人士评价：这其实只是一个缩影，现在已经有更多国产的靶向、免疫细胞治疗的药物成功出海，我们自主研发的手术机器人、人工心脏等高端的医疗设备也先后问世，应该说在这一领域中国已经走上了一条由仿到创、由弱到强的康庄大道。　　据悉，近期，全球知名金融机构也对依沃西的潜力给予了高度关注。高盛发布深度报告首次覆盖康方生物的海外合作伙伴Summit Therapeutics，并给予“买入”评级。报告指出，依沃西有望重塑超900亿美元的免疫检查点肿瘤药市场格局，预测其2041年的峰值销售额可达530亿美元。　　另一家全球知名金融机构摩根士丹利在其深度研究报告中将依沃西临床试验纳入“2025年值得关注的11个肿瘤学里程碑事件”，特别强调了其聚焦肺癌领域的HARMONi、HARMONi-2两项临床试验数据的发布，将为依沃西未来的全球发展潜力提供强有力的验证。若上述临床试验的成功，依沃西将具备与全球顶级制药公司的现有治疗方案竞争的实力，成为肿瘤免疫领域的重要新生力量。（文章来源：广州日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517809494","isCrawlerRequest":true}